Nasdaq Kron News Today

Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 597,700 shares, a drop of 74.9% from the January 15th total of 2,380,000 shares. Currently, 1.6% of the shares of the stock are sold short. Based […]

Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) COO Barbara Kosacz sold 10,676 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $1.18, for a total value of $12,597.68. Following the transaction, the chief operating officer now owns 928,966 shares of the company’s […]

Kronos Bio (NASDAQ:KRON – Free Report) had its price target cut by HC Wainwright from $9.00 to $2.50 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. Separately, Piper Sandler dropped their price objective on Kronos Bio from $7.00 to $6.00 and set an […]

Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) insider Christopher Dinsmore sold 10,032 shares of Kronos Bio stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $1.30, for a total transaction of $13,041.60. Following the completion of the transaction, the insider now owns 268,335 shares in the […]

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed...

Kronos Bio (NASDAQ:KRON – Get Free Report) had its price target reduced by analysts at HC Wainwright from $10.00 to $9.00 in a report released on Monday, Marketbeat.com reports. The firm presently has a “buy” rating on the stock. Kronos Bio Price Performance Shares of KRON stock opened at $1.42 on Monday. The business has […]

Kronos Bio (NASDAQ:KRON – Free Report) had its target price trimmed by HC Wainwright from $10.00 to $9.00 in a research note released on Monday, MarketBeat reports. The brokerage currently has a buy rating on the stock. Kronos Bio Trading Down 1.4 % Shares of Kronos Bio stock opened at $1.42 on Monday. The company […]

Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) was the target of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 3,330,000 shares, a drop of 21.5% from the June 15th total of 4,240,000 shares. Based on an average trading volume of 420,300 shares, […]

Kronos Bio, Inc. (NASDAQ:KRON – Free Report) CFO Yasir B. Al-Wakeel sold 9,617 shares of the stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $1.75, for a total transaction of $16,829.75. Following the completion of the sale, the chief financial officer now directly owns 346,102 shares […]

Privium Fund Management UK Ltd lessened its holdings in Kronos Bio, Inc. (NASDAQ:KRON – Get Rating) by 42.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 369,402 shares of the company’s stock after selling 275,929 shares during the quarter. […]